Targeting HER2 + breast cancer cells: Lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles
- 20 July 2013
- journal article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 172 (2), 395-404
- https://doi.org/10.1016/j.jconrel.2013.07.011
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Synthesis of site-specific antibody-drug conjugates using unnatural amino acidsProceedings of the National Academy of Sciences of the United States of America, 2012
- Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast CancerInternational Journal of Breast Cancer, 2012
- Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancerCancer Chemotherapy and Pharmacology, 2012
- Switching the Targeting Pathways of a Therapeutic Antibody by NanodesignAngewandte Chemie-International Edition, 2011
- Stability of Self-Assembled Polymeric Micelles in SerumMacromolecules, 2011
- A practical guide to evaluating colocalization in biological microscopyAmerican Journal of Physiology-Cell Physiology, 2011
- Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosisProceedings of the National Academy of Sciences of the United States of America, 2010
- Biorecognition and Subcellular Trafficking of HPMA Copolymer−Anti-PSMA Antibody Conjugates by Prostate Cancer CellsMolecular Pharmaceutics, 2009
- Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancerHistochemistry and Cell Biology, 2008
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005